» Articles » PMID: 16123342

Interferon-alpha As a Mediator of Polyinosinic:polycytidylic Acid-induced Type 1 Diabetes

Overview
Journal Diabetes
Specialty Endocrinology
Date 2005 Aug 27
PMID 16123342
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

A number of studies and clinical case reports have implicated interferon (IFN)-alpha as a potential mediator of type 1 diabetes pathogenesis. Administration of polyinosinic:polycytidylic acid (poly I:C), a mimic of viral double-stranded RNA, induces diabetes in C57BL/6 mice expressing the B7.1 costimulatory molecule in islets. We investigated the potential role of IFN-alpha in this disease model. The quantitative correlation between IFN-alpha levels and time to diabetes, diabetes prevention with anti-IFN-alpha antibody, and ability of IFN-alpha itself to induce diabetes are consistent with the hypothesis that poly I:C in this model acts by induction of IFN-alpha in a genetically susceptible host. Numerous recent studies highlight the importance of the innate immune system and toll receptors in determining adaptive immune responses, and we speculate that for type 1 diabetes, viral and other environmental factors may act through induction of IFNs.

Citing Articles

Toll-like receptor 3: a double-edged sword.

Hsieh M, Nishizaki D, Adashek J, Kato S, Kurzrock R Biomark Res. 2025; 13(1):32.

PMID: 39988665 PMC: 11849352. DOI: 10.1186/s40364-025-00739-5.


Changes in MDA5 and TLR3 Sensing of the Same Diabetogenic Virus Result in Different Autoimmune Disease Outcomes.

Lincez P, Shanina I, Horwitz M Front Immunol. 2021; 12:751341.

PMID: 34804036 PMC: 8602094. DOI: 10.3389/fimmu.2021.751341.


Negatively Regulates Type I Interferon-Induced Inflammation by Serving as miR-199a-5p Sponge in Type 1 Diabetes Mellitus.

Yang L, Han X, Zhang C, Sun C, Huang S, Xiao W Front Immunol. 2020; 11:576903.

PMID: 33133095 PMC: 7550460. DOI: 10.3389/fimmu.2020.576903.


DEXI, a candidate gene for type 1 diabetes, modulates rat and human pancreatic beta cell inflammation via regulation of the type I IFN/STAT signalling pathway.

Dos Santos R, Marroqui L, Velayos T, Olazagoitia-Garmendia A, Jauregi-Miguel A, Castellanos-Rubio A Diabetologia. 2018; 62(3):459-472.

PMID: 30478640 DOI: 10.1007/s00125-018-4782-0.


Targeting Innate Immunity for Type 1 Diabetes Prevention.

NeeDell J, Zipris D Curr Diab Rep. 2017; 17(11):113.

PMID: 28956297 DOI: 10.1007/s11892-017-0930-z.